Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science SummitNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Watch
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Ana M. Gonzalez-Angulo, MD

Advertisement

Articles by Ana M. Gonzalez-Angulo, MD

Triple Receptor-Negative Breast Cancer: Current and Future Treatments

ByErika N. Brown, BS, MS, PharmD,Ana M. Gonzalez-Angulo, MD
March 4th 2011

Breast cancer is the number one malignancy diagnosed in women in the United States. In 2009, it was estimated that more than 190,000 individuals would be diagnosed with breast cancer and approximately 40,000 would die from the disease.

Advertisement

Latest Updated Articles

  • Triple Receptor-Negative Breast Cancer: Current and Future Treatments
    Triple Receptor-Negative Breast Cancer: Current and Future Treatments

    March 4th 2011



Advertisement
Advertisement

Trending on OncLive

1

Dr Mesa on the FDA Approval of Ropeginterferon Alfa-2b for Essential Thrombocythemia

2

TTFields Add a New Dimension to the Changing Pancreatic Cancer Treatment Paradigm

3

Savolitinib Plus Osimertinib Improves First-Line PFS in MET-Overexpressing EGFR-Mutated NSCLC

4

ASPEN-09-03 Trial Aims to Build the Case for Evorpacept in Post–T-DXd HER2+ Breast Cancer

5

Zanidatamab Plus Chemotherapy Improves OS at Second Interim Analysis of HERIZON-GEA-01 in First-Line HER2+ GEA

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us